Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT05309616
Phase
PHASE2
Status
Completed

Conditions

  • Idiopathic Subglottic Stenosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Taltz — DRUG
    Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks

Study Details

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Key Dates

Start date
Feb 20, 2025
Status verified
May 2026
Primary completion
May 19, 2026
Completion
May 19, 2026

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Talz
    All participants receive Talz

Primary Outcome Measure

Number of weeks between operative interventions [ Time Frame: From baseline up to 12 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale New Haven HospitalNew HavenConnecticut06520-

Find similar trials in New Haven, CT

By research site
Yale New Haven Hospital· New Haven, CT

Related Studies